肿瘤患者外周血免疫指标的临床价值与展望

doi:10.3969/j.issn.1673-8640.2024.04.001

摘要/Abstract

摘要：

肿瘤局部的免疫反应和炎症反应所形成的免疫微环境在肿瘤发生、发展和转移中发挥关键作用。肿瘤免疫微环境由肿瘤细胞、免疫细胞（中性粒细胞、巨噬细胞和淋巴细胞）及其产生的细胞因子、趋化因子等构成，彼此相互作用，形成复杂的网络，影响机体免疫状态。外周血免疫指标检测可为肿瘤患者的辅助诊断、预后判断和疗效预测提供有价值的参考依据，尤其是在免疫治疗评估中具有良好的临床应用潜力。肿瘤患者个体免疫状态差异大，因此检测结果的解释具有挑战性。文章针对肿瘤患者外周血免疫指标的临床价值和应用前景进行评论。

关键词: 免疫细胞分群, 细胞因子, 肿瘤相关自身抗体, 可溶性免疫检查点, 恶性肿瘤

Abstract:

Immune microenvironment formed by local immune reaction and inflammatory responses plays a role in tumorigenesis，development and metastasis. It consists of tumor cells，immune cells（neutrophils，macrophages and lymphocytes） and the cytokines and chemokines they produce. These components interact with each other to form a complex network that affects the body's immune status. Peripheral blood immune indexes can be a valuable reference for the auxiliary diagnosis，prognosis and efficacy prediction of cancer patients，particularly in evaluating immunotherapy，which has a potential for clinical application. However，interpreting test results can be challenging due to the significant differences in individual immune status among cancer patients. This review focuses on the clinical value and potential applications of peripheral blood immune indexes in cancer patients.

Key words: Immune cell grouping, Cytokine, Tumor-associated autoantibody, Soluble immune checkpoint, Malignancy

中图分类号:

R446.1

张晗, 郭林, 卢仁泉, 陈福祥. 肿瘤患者外周血免疫指标的临床价值与展望[J]. 检验医学, 2024, 39(4): 311-316.

ZHANG Han, GUO Lin, LU Renquan, CHEN Fuxiang. Clinical value and prospect of peripheral blood immune indexes in cancer patients[J]. Laboratory Medicine, 2024, 39(4): 311-316.

参考文献 48

[1]	ZHU X, SONG H, CHEN Y, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in blood to distinguish lung cancer patients from healthy subjects[J]. Dis Markers, 2020,2020:8844698.
[2]	ZOU H, LIU S H, YANG R, et al. Combination of neutrophil-to-lymphocyte ratio and red cell distribution width with serum tumor markers for the differential diagnosis of breast cancer and its association with pathological features and molecular types[J]. Clin Breast Cancer, 2022, 22(4):e526-e535.
[3]	HESHMAT-GHAHDARIJANI K, SARMADI V, HEIDARI A, et al. The neutrophil-to-lymphocyte ratio as a new prognostic factor in cancers:a narrative review[J]. Front Oncol, 2023,13:1228076.
[4]	GÜLBEN K, BERBEROLU U, ÖNDE B, et al. Preoperative neutrophil-to-lymphocyte ratio as a predictive factor for survival in nonmetastatic colorectal cancer[J]. J Cancer Res Ther, 2020, 16(Suppl):S189-S193.
[5]	REDDY A V, HILL C S, SEHGAL S, et al. High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer[J]. J Gastrointest Oncol, 2022, 13(1):368-379. DOI PMID
[6]	MYOJIN M, HORIMOTO Y, ITO M, et al. Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer[J]. Breast Cancer, 2020, 27(4):732-738. DOI PMID
[7]	DIEM S, SCHMID S, KRAPF M, et al. Neutrophil-to-lymphocyte ratio(NLR) and platelet-to-lymphocyte ratio(PLR)as prognostic markers in patients with non-small cell lung cancer(NSCLC)treated with nivolumab[J]. Lung Cancer, 2017,111:176-181.
[8]	ZHANG L, QIN S, CHEN H, et al. Diagnostic values of the prealbumin-to-fibrinogen,albumin-to-fibrinogen,and monocyte-to-lymphocyte ratios in gastric cancer[J]. Ann Clin Lab Sci, 2021, 51(3):385-392.
[9]	XU Z, ZHANG J, ZHONG Y, et al. Predictive value of the monocyte-to-lymphocyte ratio in the diagnosis of prostate cancer[J]. Medicine(Baltimore), 2021, 100(38):e27244.
[10]	LI Y X, CHANG J Y, HE M Y, et al. Neutrophil-to-lymphocyte ratio(NLR) and monocyte-to-lymphocyte ratio(MLR) predict clinical outcome in patients with stage ⅡB cervical cancer[J]. Dis Markers, 2021,2021:2939162.
[11]	AN S, EO W, LEE S, et al. Monocyte-to-lymphocyte ratio as a determinant of survival in patients with gastric cancer undergoing gastrectomy:a cohort study[J]. Medicine(Baltimore), 2023, 102(22):e33930.
[12]	PIVATTO JÚNIOR F, SANTOS Â B S, ENGLERT E F, et al. Monocyte-to-lymphocyte ratio as predictor of cancer therapy-related cardiotoxicity in patients with breast cancer:a pilot cohort study[J]. Breast Cancer Res Treat, 2023, 200(3):355-362. DOI
[13]	ZHENG L, XIONG A, WANG S, et al. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage ⅢB-Ⅳ non-small cell lung cancer[J]. Front Immunol, 2023,14:1094378.
[14]	LIU C, CHENG H, LUO G, et al. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer[J]. Int J Oncol, 2017, 51(2):686-694. DOI PMID
[15]	LI H, YU H, LAN S, et al. Aberrant alteration of circulating lymphocyte subsets in small cell lung cancer patients treated with radiotherapy[J]. Technol Cancer Res Treat, 2021,20:15330338211039948.
[16]	BENCSIKOVA B, BUDINSKA E, SELINGEROVA I, et al. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients:a prospective study with focus on primary tumor sidedness[J]. BMC Cancer, 2019, 19(1):687. DOI
[17]	GENG R, TANG H, YOU T, et al. Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients[J]. Front Immunol, 2023,14:1125876.
[18]	AMARILLO D, BRUGNINI A, TR AS N, et al. Circulating T regulatory cell subsets in patients with untreated lung cancer[J]. Clin Transl Oncol, 2022, 24(9):1755-1763. DOI PMID
[19]	LI J, XU L, RUN Z C, et al. Multiple cytokine profiling in serum for early detection of gastric cancer[J]. World J Gastroenterol, 2018, 24(21):2269-2278. DOI URL
[20]	LIPPITZ B E, HARRIS R A. Cytokine patterns in cancer patients:a review of the correlation between interleukin 6 and prognosis[J]. Oncoimmunology, 2016, 5(5):e1093722. DOI URL
[21]	MA Y, REN Y, DAI Z J, et al. IL-6,IL-8 and TNF-α levels correlate with disease stage in breast cancer patients[J]. Adv Clin Exp Med, 2017, 26(3):421-426. DOI URL
[22]	LI L, CHEN L, ZHANG W, et al. Serum cytokine profile in patients with breast cancer[J]. Cytokine, 2017,89:173-178.
[23]	VAN DER SIJDE F, DIK W A, MUSTAFA D A M, et al. Serum cytokine levels are associated with tumor progression during folfirinox chemotherapy and overall survival in pancreatic cancer patients[J]. Front Immunol, 2022,13:898498.
[24]	NIXON A B, SCHALPER K A, JACOBS I, et al. Peripheral immune-based biomarkers in cancer immunotherapy:can we realize their predictive potential?[J]. J Immunother Cancer, 2019, 7(1):325. DOI
[25]	CUI C, DUAN Y, QIU C, et al. Identification of novel autoantibodies based on the human proteomic chips and evaluation of their performance in the detection of gastric cancer[J]. Front Oncol, 2021,11:637871.
[26]	LOU N, ZHENG C, WANG Y, et al. Identification of novel serological autoantibodies in chinese prostate cancer patients using high-throughput protein arrays[J]. Cancer Immunol Immunother, 2023, 72(1):235-247. DOI
[27]	YANG Q, YE H, SUN G, et al. Human proteome microarray identifies autoantibodies to tumor-associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma[J]. Mol Oncol, 2023, 17(5):887-900. DOI URL
[28]	ZHANG X, LIU M, ZHANG X, et al. Autoantibodies to tumor-associated antigens in lung cancer diagnosis[J]. Adv Clin Chem, 2021,103:1-45.
[29]	XIAO K, MA X, WANG Y, et al. Diagnostic value of serum tumor-associated autoantibodies in esophageal cancer[J]. Biomark Med, 2021, 15(15):1333-1343. DOI PMID
[30]	HURLEY L C, LEVIN N K, CHATTERJEE M, et al. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53[J]. Cancer Biomark, 2020, 27(3):407-421. DOI PMID
[31]	LUO M, WU S, MA Y, et al. Evaluating a panel of autoantibodies against tumor-associated antigens in human osteosarcoma[J]. Front Genet, 2022,13:872253.
[32]	LI S, MA Y, XIONG Y, et al. Five tumor-associated autoantibodies expression levels in serum predict lung cancer and associate with poor outcome[J]. Transl Cancer Res, 2019, 8(4):1364-1373. DOI URL
[33]	DEMIRCAN K, SUN Q, BENGTSSON Y, et al. Autoimmunity to selenoprotein P predicts breast cancer recurrence[J]. Redox Biol, 2022,53:102346.
[34]	TARHONI I, WAKEFIELD C J, KOLLIPARA R, et al. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition[J]. J Immunol Methods, 2021,490:112956.
[35]	ZHOU J, ZHAO J, JIA Q, et al. Peripheral blood autoantibodies against to tumor-associated antigen predict clinical outcome to immune checkpoint inhibitor-based treatment in advanced non-small cell lung cancer[J]. Front Oncol, 2021,11:625578.
[36]	CHIKUMA S. Ctla-4,an essential immune-checkpoint for T-cell activation[J]. Curr Top Microbiol Immunol, 2017,410:99-126.
[37]	GU D, AO X, YANG Y, et al. Soluble immune checkpoints in cancer:production,function and biological significance[J]. J Immunother Cancer, 2018, 6(1):132. DOI
[38]	ŚWIDERSKA J, KOZŁOWSKI M, NOWAK K, et al. Clinical relevance of soluble forms of immune checkpoint molecules sPD-1,sPD-L1,and sCTLA-4 in the diagnosis and prognosis of ovarian cancer[J]. Diagnostics(Basel), 2022, 12(1):189.
[39]	HAN S, ZHANG Y, YUAN J, et al. sPD-L1 and sPD-L2 in plasma of patients with lung cancer and their clinical significance[J]. Cytokine, 2024,176:156532.
[40]	LU K, MA H, WANG T, et al. The diagnostic value of soluble TIM-3 in oral squamous cell carcinoma[J]. Future Oncol, 2022.
[41]	WANG Q, HE Y, LI W, et al. Soluble immune checkpoint-related proteins in blood are associated with invasion and progression in non-small cell lung cancer[J]. Front Immunol, 2022,13:887916.
[42]	DO X H, LE M T, NGUYEN T H, et al. Detection of sFas,sCD137,and IL-27 cytokines as potential biomarkers for hepatocellular carcinoma diagnosis[J]. J Hepatocell Carcinoma, 2023,10:783-793.
[43]	LIU J, TIAN X, WANG Y, et al. Soluble cytotoxic T-lymphocyte-associated antigen 4(sCTLA-4)as a potential biomarker for diagnosis and evaluation of the prognosis in glioma[J]. BMC Immunol, 2021, 22(1):33. DOI
[44]	KINOSHITA R, ISHIBASHI M, HANDA H, et al. The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma[J]. Exp Hematol, 2023,121:38-47.
[45]	HONG J, CHEN X, CHEN L, et al. Clinical value of combined detection of serum sTim-3 and CEA or CA19-9 for postoperative recurrence of colorectal cancer diagnosis[J]. Cancer Manag Res, 2023,15:563-572.
[46]	KAWAKAMI H, SUNAKAWA Y, INOUE E, et al. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab:blood-based biomarker analysis for the DELIVER trial[J]. Eur J Cancer, 2023,184:10-20.
[47]	HIMURO H, NAKAHARA Y, IGARASHI Y, et al. Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors[J]. Cancer Immunol Immunother, 2023, 72(8):2829-2840. DOI PMID
[48]	LI Y, CUI X, YANG Y J, et al. Serum sPD-1 and sPD-L1 as biomarkers for evaluating the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients[J]. Clin Breast Cancer, 2019, 19(5):326-332. DOI PMID